<DOC>
	<DOCNO>NCT00134732</DOCNO>
	<brief_summary>Rotavirus ( RV ) important cause acute gastroenteritis ( GE ) require hospitalization infant young child develop develop country frequent cause death child less 5 year age ( estimate nearly 500,000 annual death worldwide ) . GlaxoSmithKline ( GSK ) Biologicals develop vaccine human rotavirus gastroenteritis . This study provide data Korean regulatory authority immunogenicity safety vaccine Korean child age 2 month time first dose .</brief_summary>
	<brief_title>Study 2 Doses Oral Live Attenuated Human Rotavirus ( HRV ) Vaccine Prophylaxis Rotavirus Gastroenteritis</brief_title>
	<detailed_description>The study consist two group child recruit different center Korea . One group receive HRV vaccine one group receive placebo . The vaccine placebo administer start 2 month age accord two dose schedule ( 0 , 2 month ) . The study consist three visit . At first visit , one blood sample take vaccination first dose administer . At second visit ( 2 month first dose ) , second vaccine administer . At third visit ( 2 month second dose ) , blood sample take . A 15-day ( Day 0 - 14 ) follow-up period observe general symptom solicit study ( fever , fussiness/irritability , diarrhea , vomit , loss appetite cough/runny nose ) . A 43-day ( Day 0 - 42 ) follow-up observe unsolicited symptom . Serious adverse event followed-up throughout study . A stool sample collect child point study he/she develop GE .</detailed_description>
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female , include , 6 12 week ( 4290 day ) age time first vaccination . Written inform consent obtain parent guardian subject . Free obvious health problem , establish medical history physical examination , enter study . Subjects vaccination history available vaccination diary card medical chart patient diary card . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine placebo , plan use study period . Planned administration vaccine ( include routine paediatric vaccine ) foresee study protocol period start 14 day dose study vaccine ( ) end 14 day . Any clinically significant history chronic gastrointestinal ( GI ) disease include uncorrected congenital malformation GI tract serious medical condition , determine investigator . History allergic disease reaction likely exacerbate component vaccine . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination ( laboratory testing require ) . Major congenital defect serious chronic illness malignant disease ( e.g . melanotic neuroectodermal tumor , malignant rhabdoid tumor , etc . ) , serious atopic dermatitis , condition result premature birth , etc . Acute disease time enrolment . ( Acute disease define presence moderate severe illness without fever i.e . temperature &gt; = 37.5°C measure axillary thermometer &gt; = 38.0°C measured rectal thermometer . A temperature great equal cutoff warrant deferral vaccination pending recovery subject . ) GE within 7 day precede study vaccine administration ( warrant deferral vaccination ) . Administration immunoglobulins and/or blood product since birth plan administration study period . Oral intake immunoglobulin via , e.g. , breastfeed allow . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug since birth . ( For corticosteroid , mean prednisone , equivalent , &gt; = 0.5 mg/kg/day . Inhaled topical steroid allow . ) Previous confirm occurrence RV GE . Household contact immunosuppressed individual</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Prophylaxis Rotavirus Gastroenteritis</keyword>
</DOC>